Glycerol phenylbutyrate

Systematic (IUPAC) name

1,2,3-Propanetriyl tris(4-phenylbutanoate)
Clinical data
Trade names	Ravicti
AHFS/Drugs.com	entry
Pregnancy category	US: C (Risk not ruled out)
Legal status	US: ℞-only
Routes of administration	Oral
Identifiers
CAS Registry Number	611168-24-2
ATC code	A16AX09
PubChem	CID 10482134
DrugBank	DB08909
ChemSpider	8657541
ChEMBL	CHEMBL2105745
Chemical data
Formula	C₃₃H₃₈O₆
Molecular mass	530.651 g/mol
SMILES C1=CC=C(C=C1)CCCC(=O)OCC(COC(=O)CCCC2=CC=CC=C2)OC(=O)CCCC3=CC=CC=C3
InChI InChI=1S/C33H38O6/c34-31(22-10-19-27-13-4-1-5-14-27)37-25-30(39-33(36)24-12-21-29-17-8-3-9-18-29)26-38-32(35)23-11-20-28-15-6-2-7-16-28/h1-9,13-18,30H,10-12,19-26H2 Key:ZSDBFLMJVAGKOU-UHFFFAOYSA-N

Glycerol phenylbutyrate (USAN), trade name Ravicti, is a medication used in the treatment of certain inborn urea cycle disorders. The medication works by preventing the harmful buildup of ammonia in the body.^[1]

References

↑ http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm337639.htm

Other alimentary tract and metabolism products (A16)

Amino acids and derivatives

Levocarnitine
Ademetionine
Levoglutamide
Cysteamine
Carglumic acid
Betaine

Enzymes

Carbohydrate metabolism: sucrase (Sacrosidase)
alpha-glucosidase (Alglucosidase alfa)

Glycolipid/sphingolipid: glucocerebrosidase (Alglucerase
Imiglucerase
Taliglucerase alfa
Velaglucerase alfa)
alpha-galactosidase (Agalsidase alfa
Agalsidase beta)

Glycosaminoglycan: iduronidase (Laronidase)
arylsulfatase B (Galsulfase)
iduronate-2-sulfatase (Idursulfase)

Other

Index of digestion

Description	Anatomy tract glands other Physiology enzymes Development

Disease	Congenital Neoplasms and cancer Inflammatory bowel disease Gluten sensitivity Other Symptoms and signs eponymous Blood tests

Treatment	Procedures Drugs anabolic steroids antacids diarrhoea and infection bile and liver functional gastrointestinal disorders laxatives peptic ulcer and reflux nausea and vomiting other Surgery